Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

April 14, 2025

Study Completion Date

April 14, 2025

Conditions
Leukemia, Myeloid
Interventions
DRUG

CC-96191

CC-96191

Trial Locations (14)

10029

Local Institution - 102, New York

13273

Local Institution - 303, Marseille

30322

Local Institution - 108, Atlanta

32224

Local Institution - 105, Jacksonville

33604

Local Institution - 301, Pessac

35233

Local Institution - 109, Birmingham

55905

Local Institution - 110, Rochester

75010

Local Institution - 304, Paris

94805

Local Institution - 302, Villejuif

98104

Local Institution - 111, Seattle

07601

Local Institution - 101, Hackensack

77030-4009

Local Institution - 107, Houston

T2N 5G2

Local Institution - 202, Calgary

M5G 2M9

Local Institution - 201, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT04789655 - Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter